Clinical Trial: GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07086404) titled 'GC012F Injection in Refractory Idiopathic Inflammatory Myopathy' on July 07.

Brief Summary: This is a single-arm, open-label, early exploratory clinical study to evaluate the safety and efficacy of GC012F Injection in subjects with refractory idiopathic inflammatory myopathy and to assess the pharmacokinetic and pharmacodynamic profiles.

This study consists of screening period, apheresis period, baseline period, lymphodepleting preconditioning period, pre-infusion evaluation period, CAR-T cell infusion period and follow-up period.

Eligible subjects will undergo apheresis and receive infusion following the manufacture of the CAR-T ...